Emergent BioSolutions | Zinsaufwendungen Für Schuld



Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 364.15M 18.56M 2025-09
ALKERMES USD 4.65M 1.35M 2024-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amarin USD 3K 5K 2024-12
ANI Pharmaceuticals USD 4.73M 711K 2025-09
BioMarin Pharmaceutical USD 2.58M 100K 2025-09
Coherus Biosciences USD 2.15M 3.2M 2025-03
Exact Sciences USD 9.79M 46K 2025-09
Exelixis USD 23.4M 3.9M 2023-09
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Heron Therapeutics USD 500K 900K 2024-09
Ionis Pharmaceuticals USD 18M 1000K 2025-09
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Lexicon Pharmaceuticals USD 2.21M 2.74M 2024-06
Lonza CHF 84M 14M 2025-06
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Myriad Genetics USD 800K 100K 2025-03
Nektar Therapeutics USD 6.02M 420K 2024-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Pacira USD 4.28M 456K 2025-09
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 2.64B 2.61B 2025-09
Sanofi EUR -25M 252M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
United Therapeutics USD 3M 4.3M 2025-09
Vanda Pharmaceuticals 601.14M 23.61M 2025-09
Xoma USD 3.4M 150K 2024-06


Emergent BioSolutions Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.